Tag Archives: Genentech
Deals Don't Need Science To Be A Success
Deals don’t need science to be a success
By Brian McGilligan, Partner, Pharmaceutical Practice, PIPC
Ex Pfizer R&D boss, John L. LaMattina recently proclaimed that Big Pharma mergers are crippling science. Whether or not you agree, mergers are a core part of business and the chances of safe-guarding future R&D investment in merged companies will best be [...]
Posted in Global, Guest Blog, Strategy Also tagged Deals, integration, mergers. M&A, Pfizer 2 Comments
Advisory Panel Rejects Avastin For Breast Cancer Treatment
An FDA advisory panel on Tuesday voted 12–1 to discontinue Avastin (bevacizumab) as a treatment for advanced breast cancer due to post-market studies stating that the treatment does not to increase patient lifespan by any significant length of time.
This is a huge problem for Roche who purchased the treatment as part of its merger with [...]
Posted in FDA, Safety Also tagged Avastin, Bevacizumab, Breast cancer, Cancer, Chemotherapy, Clinical trial, Food and Drug Administration, Roche 1 Comment
Avastin Study Shows Promising Data for Cancer Patients
Genentech released the results of its Phase III Avastin study showing that women that take the ovarian cancer treatment in tandem with chemotherapy had a 39 percent improvement in the likelihood of living longer without the disease worsening than patients being treated with just chemotherapy.
The data was released at the annual meeting of American Society [...]
Hot Topics at HBA
The 2009 Healthcare Businesswomen’s Association leadership conference is officially underway in sunny California. Last night, festivities got underway with a welcome reception for attendees followed by a “Taste of San Francisco,” which featured lively entertainment and regional cuisine.
I had the opportunity to catch up with a few seasoned participants who are widely known throughout the [...]

Genentech Runs Voluntary Corrective Ads for Boniva